
usd oct pm et
summari compani design manufactur market profession medic industri
commerci product servic global
price-to-earnings oper ep
risk assess reflect modest growth prospect
compani market good corpor
leadership solid balanc sheet compani
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct stock trade
expect total revenu grow
billion grow
organ basi see revenu grow
slightli grow
drive higher revenu ep growth
invest higher-technolog
busi new geograph market
boost growth potenti
portfolio restructur initi
led announc compani
intent spin-off dental busi
revenu lowest growth
profil oper margin four
segment see divestitur complet
septemb posit own
recent list dental busi
call envista trade ticker
nyse prior success
spun-off
recent streamlin activ invest
like drive oper ebitda margin
improv expect ebitda margin
compar
margin achiev expect
dhr effect tax rate increas
slightli
find share trade
forward earn near fair valu
consist free cash flow gener
strong balanc sheet support
continu support abil make
acquisit could acceler ep
growth find manag
experienc make integr
acquisit compani
suffer margin degrad recent year
taken mani charg relat
acquisit ge biotechnolog busi ge
biopharma much larger
recent acquisit see deal
posit competitor
immens size acquisit
could prove challeng
risk recommend target
includ difficulti ge biopharma
acquisit failur integr acquisit
advers chang foreign exchang rate
trade talk china
target base
ep estim
averag forward multipl
compani increas
exposur attract market
jan ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview danah corpor design manufactur market profession
medic industri commerci product servic research develop manufactur
sale distribut servic administr facil locat countri
approxim sale deriv custom outsid busi broken
four segment life scienc revenu diagnost dental
life scienc offer broad rang research tool scientist use studi basic build block
life includ gene protein metabolit cell order understand caus diseas
identifi new therapi test new drug vaccin segment pall corpor pall
busi also lead provid filtrat separ purif technolog
biopharmaceut food beverag medic aerospac microelectron gener industri
sector sale segment geograph destin north america
europ develop market high-growth market
diagnost segment offer analyt instrument reagent consum softwar servic
hospit physician offic refer laboratori critic care set use diagnos
diseas make treatment decis sale segment geograph destin
north america western europ develop market high-growth market
compani dental segment provid product use diagnos treat prevent diseas
ailment teeth gum support bone well improv aesthet human
smile compani lead world-wide provid broad rang dental consum equip
servic dedic drive technolog innov help dental profession improv
clinic outcom enhanc product sale segment geograph destin
north america western europ develop market high-growth market
compani environment appli solut segment offer product servic help protect
import resourc keep global food water suppli safe sale segment
geograph destin north america western europ develop market
high-growth market
corpor strategi compani seek expand revenu combin intern growth
acquisit compani histori success acquisit expect compani
remain acquisit balanc sheet cash flow support activ
impact major develop gener electr agre sell biotechnolog busi ge
biopharma billion cash februari elimin major competitor
strong track record buy integr busi immens size
acquisit could prove challeng ge biopharma lead provid instrument consum
softwar support research discoveri process develop manufactur workflow
biopharmaceut drug anticip gener billion sale
expect transact close acquir busi stand-alon
oper compani life scienc segment
septemb spun-off dental busi revenu name
envista trade publicli ticker nyse septemb own
april close billion acquisit supplier custom nucleic
acid acquir ten busi total consider million cash net cash
acquir acquir cepheid lead global molecular diagnost compani total
purchas price approxim billion seven busi total consider
million cash net cash acquir
august acquir pall corp pll billion conjunct purchas
announc plan split two separ publicly-trad compani first maintain
name would combin pll life scienc filtrat busi second name
would includ industri busi includ test measur spun
sharehold juli sharehold receiv one share share
financi trend revenu grew year-over-year billion growth
partial driven acquisit year revenu growth continu oper
improv achiev dhr five-year compound annual growth rate
compound-annual-growth-rate ep free cash flow defin cash flow oper less capit
expenditur remain steadi last sever year increas
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d septemb
vs increas valu
 composit index
vs declin
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep hold recommend share
corpor rais target price
valu share ep estim well industri
peer forward price-to-earnings averag reflect strong
momentum posit view today news acquir ge
biotechnolog instrument divis billion cash think natur
fit exist busi elimin major competitor
busi creat wide moat gap competitor
howev think may challeng relat integr busi
price tag sale forward ebitda extrem expens
fantast track record buy integr busi
purchas complet differ scale share sharpli pre-market
news think upsid next may mute
like line overal market /kevin huang cfa
pm et cfra maintain hold opinion share danah corpor
lift target in-lin
peer multipl ep estim multipl
three-year averag forward multipl
compani increas exposur attract market
acquisit ep vs higher estim
maintain ep initi ep
sale increas organ billion organ revenu
growth life scienc segment diagnost dental
environment anticip tariff china
acceler invest coupl area continu expect
insignificantli impact tariff /kevin huang cfa
analyst research note compani news
pm et cfra maintain hold opinion share danah corpor
lift target price base
multipl ep estim forward multipl
reflect compani increas exposur attract market ep
vs estim adjust ep
ep sale increas
organ billion organ revenu growth life scienc
segment diagnost environment believ
share trade slightli today compani weaker-than-expect
guidanc core revenu growth remind complet
ipo dental busi envista nr mid-septemb
end own also anticip
acquisit complet rather ge
biopharma busi call cytiva becom part /kevin
pm et cfra maintain hold opinion share danah corpor
lift target price base
multipl ep estim multipl
significantli histor forward multipl compani
increas exposur attract market ep vs
consensu estim rais ep
ep estim sale increas organ
billion organ revenu growth life scienc segment
diagnost dental environment spite
concern slow econom growth china manag confid
underli condit sale china grew year-over-year
quarter addit upcom ipo dental busi
anticip merger aim
close remain track dental busi call envista /kevin
et cfra keep hold opinion share danah corpor
lift target base multipl
ep estim multipl
three-year averag forward multipl compani
increas exposur attract market ep vs
lower estim lower ep
reflect impact recent equiti offer associ
in-progress ge biopharma acquisit lift ep
sale increas organ billion organ revenu
growth life scienc segment diagnost dental
environment despit concern around china trade tension
slowdown chines economi achiev ninth consecut quarter
double-digit growth china growth across four segment
manag appear much concern stabil
pm et cfra reiter hold opinion share danah corpor
lift price target base multipl
ep estim forward
price-to-earnings averag reflect strong momentum posit view today
news gener electr ge agre today sell biotechnolog
busi ge biopharma billion cash
elimin major competitor strong track record
buy integr busi immens size acquisit could
prove challeng ge biopharma lead provid instrument
consum softwar support research discoveri process
develop manufactur workflow biopharmaceut drug
anticip gener billion sale expect
transact close acquir busi
stand-alon oper compani life scienc segment /kevin
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
